Jesse A. Berlin
Johnson & Johnson Pharmaceutical Research and Development
37 Papers
4.8K Citations
Jesse A. Berlin is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Medicine & Odds ratio. The author has an hindex of 21, co-authored 37 publications. Previous affiliations of Jesse A. Berlin include Hospital of the University of Pennsylvania & University of Medicine and Dentistry of New Jersey.
Chat about Author
Papers
Broadening access to electronic healthcare databases.
M. Soledad Cepeda,Victor S. Lobanov,Michael Farnum,Rachel Weinstein,Peter Gates,Dimitris K. Agrafiotis,Paul E. Stang,Jesse A. Berlin +7 more
TL;DR: The Advanced Biological and Chemical Discovery system is extended to the field of outcomes research, with a high-performance relational database with a specialized data organization and indexing strategy, which decreases the data processing time by orders of magnitude compared with traditional, file-based approaches.
Genome-wide association study for empirically derived metabolic phenotypes in the Framingham Heart Study offspring cohort.
TL;DR: The genetic associations with both qualitative and quantitative representations of these empirically derived traits will provide the basis for hypothesis generation for syndromes such as the metabolic syndrome and obesity.
Benefit-risk assessment: to quantify or not to quantify, that is the question.
TL;DR: The availability of drugs and medical devices has unquestionably benefitted many patients and fundamentally changed the way healthcare is delivered, however, drug development is lengthy, and costs are staggeringly high, at least in part because of the low success rate with which newly discovered compounds achieve marketing approval.
11
Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism.
Bennett Levitan,Zhong Yuan,Alexander G.G. Turpie,Richard J. Friedman,Martin Homering,Jesse A. Berlin,Scott D. Berkowitz,Peter M DiBattiste +7 more
TL;DR: Rixaroxaban is associated with statistically significantly fewer total V TE, major VTE, and symptomatic VTE/all-cause mortality events than enoxaparin, whereas enxaparin isassociated with a smaller number of different bleeding events, although no bleeding endpoints, other than the composite of major + CRNM bleeding, were statistically significantly different.
11
Some methodological points to consider when performing systematic reviews in comparative effectiveness research.
TL;DR: It is sound advice to perform the head-to-head comparison when possible, in the relevant populations, using endpoints relevant to patients, caregivers, physicians, or payers, provided the assumptions underlying such analyses are plausible.
10